What is the recommended management of upper gastrointestinal bleeding?

Management of Upper Gastrointestinal Bleeding

For patients with acute upper gastrointestinal bleeding, initiate resuscitation immediately if hemodynamically unstable, perform risk stratification using the Glasgow-Blatchford score to identify very low-risk patients (score ≤1) who can be discharged without hospitalization, and proceed with early endoscopy within 24 hours for admitted patients. 1

Pre-Endoscopic Assessment and Management

Initial Resuscitation

• Begin resuscitation immediately for hemodynamically unstable patients with acute UGIB 1
• Use a restrictive transfusion strategy with hemoglobin threshold <80 g/L (8 g/dL) for patients without cardiovascular disease 1
• For patients with underlying cardiovascular disease, transfuse at a higher hemoglobin threshold than those without cardiovascular disease 1

Risk Stratification

• Use the Glasgow-Blatchford score ≤1 to identify very low-risk patients who do not require hospitalization or inpatient endoscopy 1
• Do NOT use the AIMS65 prognostic score for risk stratification, as it is not recommended 1
• Consider nasogastric tube placement in selected patients for prognostic value 1

Pharmacologic Pre-Endoscopic Therapy

• Administer pre-endoscopic PPI therapy to downstage the endoscopic lesion and decrease need for intervention, but do not delay endoscopy 1
• Give erythromycin infusion before endoscopy to improve visualization 2
• Do NOT routinely use promotility agents before endoscopy 1

Anticoagulation Management

• Do not delay endoscopy in patients receiving anticoagulants (vitamin K antagonists or DOACs) 1

Endoscopic Management

Timing

• Perform endoscopy within 24 hours of presentation for all admitted patients 1
• The optimal timing within 24 hours for high-risk patients remains unclear, though earlier intervention is generally preferred 3

Endoscopic Therapy Based on Lesion Characteristics

Low-Risk Stigmata (No Treatment Needed):

• Clean-based ulcer 1
• Nonprotuberant pigmented dot in ulcer bed 1

Adherent Clot (Controversial):

• Perform targeted irrigation attempting dislodgement with treatment of underlying lesion 1
• Endoscopic therapy may be considered, though intensive PPI therapy alone may be sufficient 1

High-Risk Stigmata (Treatment Required):

• Active bleeding (spurting or oozing) 1
• Visible vessel in ulcer bed 1

Endoscopic Hemostasis Techniques

Recommended Primary Methods:

• Use thermocoagulation or sclerosant injection for acutely bleeding ulcers with high-risk stigmata (strong recommendation, low-quality evidence) 1
• Through-the-scope clips can be used (conditional recommendation, very low-quality evidence) 1
• No single thermal coaptive therapy method is superior to another 1

Critical Pitfall:

• Epinephrine injection alone provides suboptimal efficacy and must be used in combination with another method 1

Adjunctive/Rescue Therapies:

• Use TC-325 hemostatic powder as temporizing therapy when conventional endoscopic therapies are unavailable or fail 1
• Do NOT use TC-325 as single therapeutic strategy versus conventional endoscopic therapy 1
• Consider over-the-scope clips (OTSCs) for recurrent ulcer bleeding after previous successful hemostasis 4, 2

Repeat Endoscopy

• Routine second-look endoscopy is not recommended 1
• Perform second attempt at endoscopic therapy in cases of rebleeding 1

Post-Endoscopic Pharmacologic Management

Proton Pump Inhibitor Therapy

For High-Risk Stigmata After Successful Endoscopic Therapy:

• Administer PPI via intravenous loading dose followed by continuous intravenous infusion for 72 hours (strong recommendation, moderate-quality evidence) 1
• After 3 days of high-dose IV PPI, use twice-daily oral PPIs through 14 days, then once daily 1
• Discharge patients with single daily-dose oral PPI for duration dictated by underlying cause 1

What NOT to Use:

• H2-receptor antagonists (HRAs) are not recommended for acute ulcer bleeding 1
• Somatostatin and octreotide are not routinely recommended for acute ulcer bleeding 1

In-Hospital Non-Endoscopic Management

Hospitalization Duration

• Hospitalize patients who underwent endoscopic hemostasis for high-risk stigmata for at least 72 hours 1
• Low-risk patients after endoscopy can be discharged promptly 1

Nutrition

• Feed low-risk patients within 24 hours after endoscopy 1
• Initiate early enteral feeding for all UGIB patients 4

Management of Failed Endoscopic Therapy

• Seek surgical consultation for patients in whom endoscopic therapy has failed 1
• Consider percutaneous embolization as alternative to surgery where available 1, 3

Helicobacter pylori Management

• Test all patients with bleeding peptic ulcers for H. pylori and provide eradication therapy if present, with confirmation of eradication 1
• Repeat negative H. pylori diagnostic tests obtained in acute setting 1

Secondary Prevention and Medication Management

NSAIDs in Patients with Previous Ulcer Bleeding

• Recognize that traditional NSAID plus PPI or COX-2 inhibitor alone carries clinically important rebleeding risk 1
• Use combination of PPI and COX-2 inhibitor to reduce recurrent bleeding risk 1

Antiplatelet Therapy

• Restart aspirin as soon as cardiovascular risk outweighs bleeding risk (typically within 7 days) 1
• Use PPI therapy with single- or dual-antiplatelet therapy (conditional recommendation, low-quality evidence) 1

Anticoagulation

• Use PPI therapy with continued anticoagulant therapy (vitamin K antagonists, DOACs) (conditional recommendation, very low-quality evidence) 1

Key Clinical Pitfalls to Avoid

1. Never use epinephrine injection as monotherapy - always combine with thermal coagulation, clips, or sclerosant 1
2. Do not perform routine second-look endoscopy - reserve for clinical rebleeding 1
3. Do not use H2-receptor antagonists for acute ulcer bleeding management 1
4. Do not delay endoscopy in anticoagulated patients 1
5. Do not discharge high-risk patients early - maintain 72-hour observation after endoscopic hemostasis 1
6. Do not forget H. pylori testing and eradication with confirmation 1